T2 Biosystems

T2 Biosystems is dedicated to the rapid detection of sepsis-causing pathogens. The company, established in 2006 and headquartered in the United States, focuses on developing innovative diagnostic products to improve patient health, particularly targeting sepsis, hemostasis, bacteria, and Lyme disease - all areas of significant unmet medical need. Utilizing its proprietary T2 Magnetic Resonance platform (T2MR®), T2 Biosystems aims to lower mortality rates, improve patient outcomes, and reduce healthcare costs by enabling medical professionals to make targeted treatment decisions earlier. As an emerging leader in the field of in vitro diagnostics, T2 Biosystems has received a $15.00MPost-IPO Equity investment from CRG on 15 February 2024. With two FDA-cleared products targeting sepsis, the company continues to develop a broad set of applications to drive positive change in the medical diagnostic landscape. For individuals passionate about advancing healthcare, T2 Biosystems offers opportunities to contribute to its mission through open positions available at www.t2biosystems.com/careers.